← Leaderboards
Ada S Cowan
Metallopharm, Llc
$2,626,413
Attributed
$2,626,413
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $844K · FY2009–16$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,626,413 · 3
By mechanism
R44$1,957,389 · 1
R43$669,024 · 2
Top collaborators
No co-investigators on record.
Most similar at Metallopharm, Llc
Same institution · by research overlap
- Donna T Palmer$156,722
- San Ching$100,000
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionCessation Of LifePeptide HydrolasesVirusInterferonsMetalsToxic EffectPharmaceutical PreparationsInhibitor/AntagonistBinding (Molecular Function)Anti-Hepatitis CLeadMalignant Neoplasm Of LiverChemistryBloodDoseChronic Hepatitis CCirrhosisHepatitis CHepatitis C VirusRepliconBiodistributionViralLife
Grant awards (6)
Rapid point-of-care diagnosis of wound infection$224,974
R43 · FY2016 · NR · contact PI
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$300,311
R44 · FY2013 · AA · contact PI
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$813,038
R44 · FY2012 · AA · contact PI
Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection$844,040
R44 · FY2011 · AA · contact PI
Metallodrugs Targeting HCV Protease$222,025
R43 · FY2010 · AA · contact PI
Metallodrugs Targeting HCV Protease$222,025
R43 · FY2009 · AA · contact PI